Fingerprint
Dive into the research topics of 'JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy
Elisa Gremese, Stefano Alivernini, Barbara Tolusso, Martin P. Zeidler, Gianfranco Ferraccioli
Research output: Contribution to journal › Article
14
Citations
(Scopus)